| | | | | - Top investment opportunities
- OurCrowd launches Global Health Equity Fund with WHO Foundation
- Pfizer signs $110M deal with CytoReason, invests $20M
- Startup of the Week: Largix, saving manpower with futuristic autonomous production technology
- OurCrowd hosts Confederation of Indian Industry
- Binah.ai unveils blood count, cholesterol level detection via smartphone
- Leading Spanish health insurer inks nationwide deal with TytoCare
- IMVU taps Spectrum Labs' AI to identify positive online behavior, raise revenue
- ByondXR builds metaverse storefronts for P&G, YSL and Deutsche Telekom
- Introductions
- More than 4,300 high-tech jobs
OurCrowd launches Global Health Equity Fund with WHO Foundation 
On Monday, at the Clinton Global Initiative meeting in New York, I joined Anil Soni, CEO of the WHO Foundation, to announce a Global Health Equity Fund launched by the WHO Foundation and OurCrowd, a $200M financial-first impact fund that will focus on breakthrough technology solutions to improve healthcare around the world. It will support the UN's sustainable development goals, kick-start innovation, and increase investment in the health sector. Its mission is to increase equitable access to medical care while also delivering competitive returns to investors. Companies receiving investment from the Fund will have to agree to an Access Pledge, ensuring that their technology solutions are available, accessible, appropriate, and affordable for populations experiencing inequity, particularly in low- and middle-income settings. Our announcement triggered a wave of global news coverage, including the Wall Street Journal, Forbes, Reuters, CNBC TV Africa, TechCrunch and The Times of Israel. I explain our plans in my new 'Investors on the Frontlines' column. 
Pfizer signs $110M deal with CytoReason, invests $20M 
Pfizer is upping the ante in its collaboration with CytoReason. The pharma giant is expanding its ongoing strategic collaboration with our portfolio company in a deal that could reach $110M over the next five years, Calcalist reports. Under the terms of the agreement, Pfizer will also make a $20M equity investment, have options to license CytoReason's technology, and fund supplementary project support. CytoReason's platform runs disease models, the results of which support Pfizer's drug development programs. "CytoReason's biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost effective," says Mikael Dolsten, Pfizer's Chief Scientific Officer and President. Startup of the Week
Largix: Saving manpower with futuristic autonomous production technology
 The manufacturing world faces a manpower crisis, with severe labor shortages having a major impact on a wide array of industries. Israeli startup Largix is rising to the challenge, bringing its autonomous, digital Additive Production System (APS) to help replace the skills of absent workers. Largix is the first company to commercially produce 3D robotic printers capable of producing room-size, industrial-grade products using common thermoplastic polymers. It is pursuing clients in the construction and infrastructure industries, along with producers of custom-made chemical storage tanks. The company estimates its technology will help manufacturers cut production costs in half and improve overall productivity by 15X. Largix forecasts 200-300% YOY growth in income through 2026 from US and European customers, generated from the sales of the APS, polymers and SaaS model. It has signed contracts with two clients, A.A.H Plast in Israel and CGK Group in Belgium, which also will serve as Beta sites for the company's technology. OurCrowd is leading Largix's current funding round at a 20% discount. 
OurCrowd hosts Confederation of Indian Industry 
We were honored to host a delegation from the Confederation of Indian Industry at OurCrowd's headquarters in Jerusalem. They were in Israel as part of a collaboration with the Israeli economic missions in the UAE and New Delhi. We discussed OurCrowd's activities in the UAE and the enormous potential of the relationship between the UAE, India and Israel. 
|
| | | | | | | | |
0 Comments